| 臺大學術典藏 |
2022-02-22T05:34:18Z |
Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies
|
Chen B.-B.; Shih I.-L.; Wu C.-H.; Hsu C.; CHIEN-HUNG CHEN; Shih T.T.-F.; Liu K.-L.; Liang P.-C. |
| 臺大學術典藏 |
2022-02-22T05:34:17Z |
Hepatitis B and C viruses are not risks for pancreatic adenocarcinoma
|
Chang M.-C.; CHIEN-HUNG CHEN; Liang J.-D.; Tien Y.-W.; Hsu C.; Wong J.-M.; Chang Y.-T. |
| 臺大學術典藏 |
2022-02-22T05:34:16Z |
Consensus development from the 5th asia-pacific primary liver cancer expert meeting (APPLE 2014)
|
Hsu C.; Chen B.-B.; CHIEN-HUNG CHEN; Ho M.-C.; Cheng J.C.-H.; Kokudo N.; Murakami T.; Yeo W.; Seong J.; Jia J.-D.; Han K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-22T05:34:15Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2022-02-22T05:34:10Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; CHIEN-HUNG CHEN; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-02-22T05:34:08Z |
Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy
|
Shen Y.-C.; Yeh C.-P.; Jeng Y.-M.; Hsu C.; Hsu C.-H.; Lin Z.-Z.; Shao Y.-Y.; Lu L.-C.; Liu T.-H.; CHIEN-HUNG CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-21T02:51:54Z |
Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy
|
YING-CHUN SHEN; Yeh C.-P.; Jeng Y.-M.; Hsu C.; Hsu C.-H.; Lin Z.-Z.; Shao Y.-Y.; Lu L.-C.; Liu T.-H.; Chen C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-21T02:04:36Z |
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
|
Ou D.-L.; Chen C.-W.; Hsu C.-L.; Chung C.-H.; Feng Z.-R.; Lee B.-S.; ANN-LII CHENG; Yang M.-H.; Hsu C. |
| 臺大學術典藏 |
2022-02-21T02:04:35Z |
Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
|
Hsu C.-L.; Ou D.-L.; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; ANN-LII CHENG; Jeng Y.-M.; Hsu C. |
| 臺大學術典藏 |
2022-02-21T02:04:34Z |
Eg5 as a prognostic biomarker and potential therapeutic target for hepatocellular carcinoma
|
Shao Y.-Y.; Sun N.-Y.; Jeng Y.-M.; Wu Y.-M.; Hsu C.; Hsu C.-H.; Hsu H.-C.; ANN-LII CHENG; Lin Z.-Z. |
| 臺大學術典藏 |
2022-02-21T02:04:33Z |
Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma
|
Chen B.-B.; Shao Y.-Y.; Lin Z.-Z.; Hsu C.-H.; ANN-LII CHENG; Hsu C.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-02-16T03:16:57Z |
Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma
|
Chen B.-B.; YU-YUN SHAO; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.; Hsu C.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-02-16T03:16:57Z |
Eg5 as a prognostic biomarker and potential therapeutic target for hepatocellular carcinoma
|
YU-YUN SHAO; Sun N.-Y.; Jeng Y.-M.; Wu Y.-M.; Hsu C.; Hsu C.-H.; Hsu H.-C.; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2022-02-16T03:16:56Z |
Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy
|
Shen Y.-C.; Yeh C.-P.; Jeng Y.-M.; Hsu C.; Hsu C.-H.; Lin Z.-Z.; YU-YUN SHAO; Lu L.-C.; Liu T.-H.; Chen C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-16T03:16:56Z |
Early changes in dce-mri biomarkers may predict survival outcomes in patients with advanced hepatocellular carcinoma after sorafenib failure: Two prospective phase ii trials
|
Chen B.-B.; Lin Z.-Z.; YU-YUN SHAO; Hsu C.; Hsu C.-H.; Cheng A.-L.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022-02-14T07:10:49Z |
Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
|
Hsu C.-L.; Ou D.-L.; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; Cheng A.-L.; YUNG-MING JENG; Hsu C. |
| 臺大學術典藏 |
2022-02-14T07:10:49Z |
Eg5 as a prognostic biomarker and potential therapeutic target for hepatocellular carcinoma
|
Shao Y.-Y.; Sun N.-Y.; YUNG-MING JENG; Wu Y.-M.; Hsu C.; Hsu C.-H.; Hsu H.-C.; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2022-02-14T07:10:48Z |
Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy
|
Shen Y.-C.; Yeh C.-P.; YUNG-MING JENG; Hsu C.; Hsu C.-H.; Lin Z.-Z.; Shao Y.-Y.; Lu L.-C.; Liu T.-H.; Chen C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-08T06:27:20Z |
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
|
DA-LIANG OU; Chen C.-W.; Hsu C.-L.; Chung C.-H.; Feng Z.-R.; Lee B.-S.; Cheng A.-L.; Yang M.-H.; Hsu C. |
| 臺大學術典藏 |
2022-02-08T06:27:19Z |
Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
|
Hsu C.-L.; DA-LIANG OU; Bai L.-Y.; Chen C.-W.; Lin L.; Huang S.-F.; Cheng A.-L.; Jeng Y.-M.; Hsu C. |
| 臺大學術典藏 |
2022-02-08T06:27:17Z |
Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer
|
Hsieh C.-H.; Jian C.-Z.; Lin L.-I.; Low G.-S.; Ou P.-Y.; Hsu C.; DA-LIANG OU |
| 臺大學術典藏 |
2022-02-07T03:29:06Z |
Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma
|
Hung Y.-P.; Shao Y.-Y.; Lee J.-M.; Hsu C.; CHIH-HUNG HSU; Yang M.-H.; Chao Y. |
| 臺大學術典藏 |
2022-02-07T03:29:05Z |
The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma
|
Hung Y.-P.; Shao Y.-Y.; Hsu C.; CHIH-HUNG HSU; Lee J.-M.; Yang M.-H.; Chao Y. |
| 臺大學術典藏 |
2022-02-07T03:29:05Z |
Eg5 as a prognostic biomarker and potential therapeutic target for hepatocellular carcinoma
|
Shao Y.-Y.; Sun N.-Y.; Jeng Y.-M.; Wu Y.-M.; Hsu C.; CHIH-HUNG HSU; Hsu H.-C.; Cheng A.-L.; Lin Z.-Z. |
| 臺大學術典藏 |
2022-02-07T03:29:04Z |
Dynamic contrast-enhanced and intravoxel incoherent motion mri biomarkers are correlated to survival outcome in advanced hepatocellular carcinoma
|
Chen B.-B.; Shao Y.-Y.; Lin Z.-Z.; CHIH-HUNG HSU; Cheng A.-L.; Hsu C.; Liang P.-C.; Shih T.T.-F. |
